OPTUS Pharmaceutical Co., Ltd.

A131030

KR7131030009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6,300 ^KRW	-0.47%		+4.30%	+18.42%

2023	OPTUS Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	Tranche Update on OPTUS Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 7, 2022.	CI

DHP Korea Co., Ltd. authorizes a Buyback Plan.

March 22, 2020

The Board of Directors of DHP Korea Co., Ltd. has authorized a buyback plan on March 23, 2020.

Latest news about OPTUS Pharmaceutical Co., Ltd.

OPTUS Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on OPTUS Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 7, 2022.	22-10-18	CI
OPTUS Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 7, 2022 has closed with 463,678 shares, representing 2.97% for KRW 2,944.46 million.	22-10-17	CI
OPTUS Pharmaceutical Co., Ltd. announces an Equity Buyback for 463,678 shares.	22-09-07	CI
OPTUS Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-09-06	CI
Tranche Update on DHP Korea Co., Ltd.'s Equity Buyback Plan announced on January 21, 2022.	22-03-22	CI
DHP Korea Co., Ltd.'s Equity Buyback announced on January 21, 2022, has expired with 411,635 shares, representing 2.57% for KRW 3,001.58 million.	22-03-22	CI
DHP Korea Co., Ltd. announces an Equity Buyback for 416,088 shares.	22-01-21	CI
DHP Korea Co., Ltd. authorizes a Buyback Plan.	22-01-20	CI
Tranche Update on DHP Korea Co., Ltd.'s Equity Buyback Plan announced on March 23, 2020.	20-06-23	CI
Tranche Update on DHP Korea Co., Ltd.'s Equity Buyback Plan announced on March 23, 2020.	20-06-23	CI
DHP Korea Co., Ltd.'s Equity Buyback announced on March 23, 2020, has expired with 283,523 shares, representing 1.74% for KRW 2,015.98 million.	20-06-22	CI
DHP Korea Co., Ltd. announces an Equity Buyback for 373,134 shares.	20-03-22	CI
DHP Korea Co., Ltd. authorizes a Buyback Plan.	20-03-22	CI
DHP Korea Co., Ltd.(KOSDAQ:A131030) dropped from S&P Global BMI Index	19-09-23	CI
Allianz Global Investors Korea Limited acquired additional 1.75% stake in DHP Korea Co., Ltd..	17-01-08	CI
DHP Korea Co., Ltd.(KOSDAQ:A131030) added to S&P Global BMI Index	15-09-21	CI
Truston Asset Management Co., Ltd. and a related company acquired 5.25% in DHP Korea Co., Ltd..	15-06-22	CI
DHP Korea Ltd. completed the acquisition of HI Special Purpose Acquisition Company I from Eugene Asset Management Co., Ltd. and other shareholders in a reverse merger transaction.	13-11-13	CI
DHP Korea Ltd. entered into an agreement to acquire HI Special Purpose Acquisition Company I from Eugene Asset Management Co., Ltd. and other shareholders in a reverse merger transaction.	13-06-25	CI
Sam Chun Dang Pharm. Co.,Ltd completed the acquisition of 61.27% stake in DHP Korea Ltd.	12-12-26	CI
Sam Chun Dang Pharm. Co.,Ltd agreed to acquire 61.27% stake in DHP Korea Ltd. for approximately KRW 14 billion.	12-12-25	CI

Chart OPTUS Pharmaceutical Co., Ltd.

Duration

Period

More charts

Optus Pharmaceutical Co Ltd, formerly DHP Korea Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company is primarily engaged in the manufacture and sale of eye drops and ophthalmic preparations such as dry eye treatment agents, conjunctivitis treatment agents, anti-inflammatory medication agents, glaucoma treatment agents and others.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
OPTUS PHARMACEUTICAL CO., LTD.	+18.42%	73.53M
KYOWA KIRIN CO. LTD.	+12.41%	9B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+5.23%	3.9B
INDIVIOR PLC	+20.51%	2.45B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+3.94%	1.65B